J. Vernon Odom, Ph.D. (University of North Carolina at Greensboro),Professor, West Virginia University Eye Institute Professor, Department of Physiology and Pharmacology, West Virginia University Board of Directors, Smith-Kettlewell Eye Research Institute. Dr. Odom's research aims to understand and modeling fundamental and higher order visual processes and their development over the lifespan in normal patients and those with eye diseases. Processes, which are of special interest, include binocular interactions, visual acuity, optic flow and photophobia. He has uses a combination of questionnaire, behavioral, electrophysiological, and functional magnetic resonance imaging methods to understand these processes.
J. Vernon Odom, Ph.D. (University of North Carolina at Greensboro),Professor, West Virginia University Eye Institute Professor, Department of Physiology and Pharmacology, West Virginia University Board of Directors, Smith-Kettlewell Eye Research Institute. Dr. Odom's research aims to understand and modeling fundamental and higher order visual processes and their development over the lifespan in normal patients and those with eye diseases. Processes, which are of special interest, include binocular interactions, visual acuity, optic flow and photophobia. He has uses a combination of questionnaire, behavioral, electrophysiological, and functional magnetic resonance imaging methods to understand these processes.
Dr. Davidorf is a well-recognized expert in the field of ophthalmology, especially for his work in ocular melanoma. He is a respected leader and accomplished in all three department mission areas: Education, Research, and Clinical Care. He has been on faculty at The Ohio State University for over 40 years and is beloved by patients and students, residents, and fellows for his extensive knowledge and easy-going manner. During his tenure as director of the retina division, Dr. Davidorf established a national reputation for both patient care and research, participating in scores of clinical trials. He is known as a pioneer
Dr. Davidorf is a well-recognized expert in the field of ophthalmology, especially for his work in ocular melanoma. He is a respected leader and accomplished in all three department mission areas: Education, Research, and Clinical Care. He has been on faculty at The Ohio State University for over 40 years and is beloved by patients and students, residents, and fellows for his extensive knowledge and easy-going manner. During his tenure as director of the retina division, Dr. Davidorf established a national reputation for both patient care and research, participating in scores of clinical trials. He is known as a pioneer in the conservative management of ocular melanoma and introduced brachytherapy as an alternative to enucleation in the US. He was instrumental in establishing the OSU Ocular Melanoma Study Group, a multidisciplinary team focused on improving the prognosis for cancer patients. Dr. Davidorf has published over 200 journal articles, authored 2 textbooks and numerous book chapters. He is an outstanding teacher, talented vitro-retinal surgeon, and dedicated researcher.
Dr. Naj Sharif is a graduate of Southampton University, England (UK) where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). Dr. Sharif has been in the pharmaceutical industry for >30-years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Executive Director, R&D Division). Dr. Sharifs 23-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan, Patanol, Emedine, Simbrinza, Izba and Pazeo to treat glaucoma/ocular hypertension and
Dr. Naj Sharif is a graduate of Southampton University, England (UK) where he received his BSc (Joint Honors: Biochemistry and Physiology) and his PhD (Neuroscience). Dr. Sharif has been in the pharmaceutical industry for >30-years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Executive Director, R&D Division). Dr. Sharifs 23-tenure at Alcon resulted in his contributions to the discovery/development and US FDA approvals of Travatan, Patanol, Emedine, Simbrinza, Izba and Pazeo to treat glaucoma/ocular hypertension and ocular allergies. He was recently co-responsible for acquiring Innfocus Inc for Santen, and has thus helped add a device for glaucoma treatment to the product pipeline of Santen. Dr. Sharif was recently elected as a Fellow of ARVO (FARVO), and Fellow of British Pharmacological Society (BPS) (FBPhS) for his exemplary service on numerous committees, progress on drug discovery, and advancement of scientific reputation of both societies. He was honored as the first recipient of the inaugural Dr. Roger Vogel award for pharmaceutical research presented by the ARVO Foundation (2014), and the "Sir James Black Award" for contributions to drug discovery from BPS (2017). He has been an organizer, chairman and invited Keynote speaker at numerous global conferences, symposia and workshops. Dr. Sharif serves on the editorial boards of numerous scientific journals, is an Adjunct Professor at several universities, and a thesis advisor for MS- and PhD-level students. He has published >200 scientific articles and edited 2 books on imaging in neuroscience. Dr. Sharif is also the holder of 23 issued US and EU patents on ocular cell-lines and small drug molecules to treat human diseases of the CNS and the eye. His research interests span ocular and CNS pharmacology, cellular signal transduction mechanisms, and drug discovery and development.
Dr. Kowluru is a Professor of Ophthalmology and Anatomy/Cell Biology at Wayne State University, Detroit. She also holds a joint appointment in the Endocrinology department. Her research is focused on understanding the molecular mechanism of diabetic retinopathy and the metabolic memory associated with its continued progression, especially understanding the role of mitochondrial dysfunction and epigenetic modifications. Dr. Kowluru has more than 20 years of experience in diabetic retinopathy research, and has published over 125 peer-reviewed articles. She is on the editorial board of Investigative Ophthalmology and Visual Sciences, Expert Opinion on Investigational Drugs, and many other Vision and Diabetes journals.
Dr. Kowluru is a Professor of Ophthalmology and Anatomy/Cell Biology at Wayne State University, Detroit. She also holds a joint appointment in the Endocrinology department. Her research is focused on understanding the molecular mechanism of diabetic retinopathy and the metabolic memory associated with its continued progression, especially understanding the role of mitochondrial dysfunction and epigenetic modifications. Dr. Kowluru has more than 20 years of experience in diabetic retinopathy research, and has published over 125 peer-reviewed articles. She is on the editorial board of Investigative Ophthalmology and Visual Sciences, Expert Opinion on Investigational Drugs, and many other Vision and Diabetes journals. She serves on a number of review panels including the National Institutes of Health, Juvenile Diabetes Research Foundation and Veterans Administration.
1. Contribution over a hundred and fifty peer review publications in the ophthalmic literature 2. Specialization in medical and surgical retina and infections inflammations (uveitis), above all ocular toxoplasmosis and bacterial adhesion to intraocular lens 3. Board of the French agency for drug security (AFSSAPS) and of the French Health Agency (HAS) since 2005 to 2012 4. Expert for the French Health
1. Contribution over a hundred and fifty peer review publications in the ophthalmic literature 2. Specialization in medical and surgical retina and infections inflammations (uveitis), above all ocular toxoplasmosis and bacterial adhesion to intraocular lens 3. Board of the French agency for drug security (AFSSAPS) and of the French Health Agency (HAS) since 2005 to 2012 4. Expert for the French Health Minister about Clinical Research Projects in University Hospitals since 2009 5. Principal investigator and national coordinator of the GEFAL trial (avastin versus lucentis in AMD) 6. Member of numerous scientific societies 7. Honoraria forconsulting/speaking orfor advisory board articipation or Grants from Alcon, Allergan,Alimera,Bausch et Lomb, Bayer, Novartis, Thea.
Dr. Sohan Singh Hayreh received his MD in 1951 and then Master of Surgery degree in India, and after that Ph.D. from London University. He worked as a Research Fellow for 3 years from 1961 onwards with Sir Stewart Duke-Elder at the Institute of Ophthalmology, University of London. After that he obtained Fellowships of the Royal Colleges of Surgeons of Edinburgh and England, and was elected as Honorary Fellow of the Royal College of Ophthalmologists. Dr. Hayreh is a clinical scientist. Since 1955, he has been actively involved in basic, experimental and clinical ophthalmic research; his major fields of research
Dr. Sohan Singh Hayreh received his MD in 1951 and then Master of Surgery degree in India, and after that Ph.D. from London University. He worked as a Research Fellow for 3 years from 1961 onwards with Sir Stewart Duke-Elder at the Institute of Ophthalmology, University of London. After that he obtained Fellowships of the Royal Colleges of Surgeons of Edinburgh and England, and was elected as Honorary Fellow of the Royal College of Ophthalmologists. Dr. Hayreh is a clinical scientist. Since 1955, he has been actively involved in basic, experimental and clinical ophthalmic research; his major fields of research and clinical activity have been the field of ocular vascular occlusive disorders. He has published more than 400 research papers and 50 chapters. In 1987, the University of London, in recognition of his research deemed 'original and seminal in nature', awarded him its highest and prestigious degree of Doctor of Science in Medicine.
Aladin M. Boriek, PhD is a Professor of Medicine and Physiology at Baylor College of Medicine. Dr. Boriek received a master degree from University of Michigan in 1984 and a PhD degree from Rice University in 1990. He completed his postdoctoral training at Baylor College of Medicine in respiratory mechanics under the mentorship of Dr. Rodarte. Dr. Boriek has been a regular member of the Respiratory Integrative Biology and Translational Research Study Section (2005-2009). Dr. Boriek has served on other NIH study sections including The Respiratory and Applied Physiology, and The Skeletal Muscle Biology and Exercise Physiology, and The
Aladin M. Boriek, PhD is a Professor of Medicine and Physiology at Baylor College of Medicine. Dr. Boriek received a master degree from University of Michigan in 1984 and a PhD degree from Rice University in 1990. He completed his postdoctoral training at Baylor College of Medicine in respiratory mechanics under the mentorship of Dr. Rodarte. Dr. Boriek has been a regular member of the Respiratory Integrative Biology and Translational Research Study Section (2005-2009). Dr. Boriek has served on other NIH study sections including The Respiratory and Applied Physiology, and The Skeletal Muscle Biology and Exercise Physiology, and The Bioengineering and Physiology. He has also served as an external reviewer for the Surgery Review Board of the Department of Veteran Affairs, the Canadian Institutes of Health Research, the Canadian Lung Association /Canadian Thoracic Society, the Research Grant Council of Hong Kong. He has also served on numerous review panels for the National Science Foundation. He served as a member of the editorial Board of the Journal of Applied Physiology (2000-2008). Dr. Boriek has published nearly sixty papers in peer reviewed journals. Dr. Boriek's research interests include respiratory muscle mechanics, mechanical signal transduction, and muscular dystrophy.
Dr. Chang-Ning Liu is a Principal Scientist and Drug Safety Team Lead in the Drug Safety R & D at Pfizer Inc. Prior to joining Pfizer, he served as an Associate Research Scientist at Yale University School of Medicine (2000-2002) and completed a postdoctoral fellowship at Hebrew University of Jerusalem in Israel (1997-2000). He received his PhD degree in neuroscience from China Academy of Chinese Medical Sciences in 1994. His research interests include small molecule and biologic drug-induced ocular toxicity, particularly retinal toxicity, and neuropathy in preclinical rodent and non-rodent species. He is also familiar with assessment of ocular toxicity
Dr. Chang-Ning Liu is a Principal Scientist and Drug Safety Team Lead in the Drug Safety R & D at Pfizer Inc. Prior to joining Pfizer, he served as an Associate Research Scientist at Yale University School of Medicine (2000-2002) and completed a postdoctoral fellowship at Hebrew University of Jerusalem in Israel (1997-2000). He received his PhD degree in neuroscience from China Academy of Chinese Medical Sciences in 1994. His research interests include small molecule and biologic drug-induced ocular toxicity, particularly retinal toxicity, and neuropathy in preclinical rodent and non-rodent species. He is also familiar with assessment of ocular toxicity in toxicology studies conducted for regulatory purpose.
Dr. Patricia A. D Amore received a B.A. in 1973 from Regis College, a Ph.D. in Biology from Boston University in 1977, and conducted a postdoctoral fellowship in Biological Chemistry and Ophthalmology at Johns Hopkins Medical School. In 1987, Dr. D Amore obtained an MBA from Northeastern University. She became a Professor of Ophthalmology & Pathology In 2006, she received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, and in 2012 the Rous-Whipple Award for the American Society of Investigative Pathology. She is the Director of Research at Schepens and the Ankeny Scholar of Retinal Molecular
Dr. Patricia A. D Amore received a B.A. in 1973 from Regis College, a Ph.D. in Biology from Boston University in 1977, and conducted a postdoctoral fellowship in Biological Chemistry and Ophthalmology at Johns Hopkins Medical School. In 1987, Dr. D Amore obtained an MBA from Northeastern University. She became a Professor of Ophthalmology & Pathology In 2006, she received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, and in 2012 the Rous-Whipple Award for the American Society of Investigative Pathology. She is the Director of Research at Schepens and the Ankeny Scholar of Retinal Molecular Biology and the Associate Chief of Basic and Translational Research at Massachusetts Eye and Ear. Her research focuses on understanding the mechanism of vascular growth and developmentand the contribution of cell-cell interactions in the cells of the vasculature.
G Astrid Limb is a Professor of Retinal Stem Cell Biology and Therapeutics at the UCL Institute of Ophthalmology in London. She obtained her PhD in 1987 working under the supervision of Prof DC Dumonde at St. Thomas’ Hospital Medical School, London. She was awarded a Fellowship of the Royal College of Pathologists in the UK in 2009. She has served in various Committees of the Association for Research in Vision and Ophthalmology (ARVO) and in several review panels from European funding bodies. Her research focuses on the development of regenerative therapies for the neural retina, based on
G Astrid Limb is a Professor of Retinal Stem Cell Biology and Therapeutics at the UCL Institute of Ophthalmology in London. She obtained her PhD in 1987 working under the supervision of Prof DC Dumonde at St. Thomas’ Hospital Medical School, London. She was awarded a Fellowship of the Royal College of Pathologists in the UK in 2009. She has served in various Committees of the Association for Research in Vision and Ophthalmology (ARVO) and in several review panels from European funding bodies. Her research focuses on the development of regenerative therapies for the neural retina, based on the application of Müller glia with stem cell characteristics for neural cell replacement and on the elucidation of cellular and molecular mechanisms that may induce these cells to endogenously repair of the human retina without the need for transplantation.
Jesus Porta-Etessam gained a degree in medicine from the Universidad Complutense de Madrid and made the residence of neurology at the University Hospital 12 de Octubre of Madrid, and completed his training in Neuro-Sloan Kettering Center in New York. He currently works as a neurologist at the Hospital Clinico San Carlos of Madrid at the Unit Neurootooftalmologia Headaches, where he is one of the fellow tutors; And he is the Head of de Neurological Department in Clinica La Luz. He is an Associate Professor of medicine at the UCM. He is in the Board of Directors of the Spanish Society
Jesus Porta-Etessam gained a degree in medicine from the Universidad Complutense de Madrid and made the residence of neurology at the University Hospital 12 de Octubre of Madrid, and completed his training in Neuro-Sloan Kettering Center in New York. He currently works as a neurologist at the Hospital Clinico San Carlos of Madrid at the Unit Neurootooftalmologia Headaches, where he is one of the fellow tutors; And he is the Head of de Neurological Department in Clinica La Luz. He is an Associate Professor of medicine at the UCM. He is in the Board of Directors of the Spanish Society of Neurology, where he worked as a Member of International Relations and of the Madrid Association of Neurology. He is member of the neurology National comission. He serves on the board of the study group of neuro-ophthalmology and headache which is one of the promoters. He serves as a Member of the Editorial Boards of the Journal of Neurology and Neuroscience, Headache Research and Treatment, Neurologia, Revista de Neurologia, Boletin del Dolor and Lancet Neurology (Spanish edition) and regular reviewer of national and international journals. He works as an honorary member of several associations of patients. In addition, he is the Coordinator of the Online Platform PCI and the Scientific Director of the Applied Neuroscience club. He has published over 200 articles in national and international journals, more than 20 chapters and has edited several books. He has been the organizer and speaker at numerous conferences and meetings. Porta-Etessam has participated in several clinical and therapeutic studies.
Cristiano Giusti was born in Rome, Italy, in 1965. He received his MD degree summa cum laude in 1991 at the University La Sapienza of Rome where he also became specialist in Ophthalmology in 1996 and got a master degree in Laser Applications in Ophthalmology in 1997. He is Consultant of the Research Ethics Committee and Assistant Chief Clinical Officer at the Department of Ophthalmology, University Hospital Campus Bio-Medical of Rome. He is author of several scientific publications, with special interests in medical retina (diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy). He is member of the Editorial Board for: European
Cristiano Giusti was born in Rome, Italy, in 1965. He received his MD degree summa cum laude in 1991 at the University La Sapienza of Rome where he also became specialist in Ophthalmology in 1996 and got a master degree in Laser Applications in Ophthalmology in 1997. He is Consultant of the Research Ethics Committee and Assistant Chief Clinical Officer at the Department of Ophthalmology, University Hospital Campus Bio-Medical of Rome. He is author of several scientific publications, with special interests in medical retina (diabetic retinopathy, retinitis pigmentosa, central serous chorioretinopathy). He is member of the Editorial Board for: European Review for Medical and Pharmacological Sciences,Medical Hypothesis, Discovery and Innovation (MEHDI) in Ophthalmology, Journal of Neurology and Clinical Neuroscience, Clinical Journal of Ophthalmology. He is reviewer for several renowned international journals (Blood, Coagulation & Fibrinolysis,Journal of Diabetes and its Complications, Treatments in Endocrinology, Expert Review of Ophthalmology, Saudi Medical Journal,Pediatric Diabetes, Molecular Vision).
Francesco Pichi was born and raised in Italy where he undertook much of his training. He received his medical degree withhigh honors from the Alma Mater Studiorum of Bologna and completed a medical internship. He has participated inobservership programs in Medical Retina and Uveitis at Moorfields Eye Hospital (London), Bascom Palmer EyeInstitute (Miami) and Cole Eye Institute (Cleveland). He is currently receiving his ophthalmology residency education at the University of Milan.
Francesco Pichi was born and raised in Italy where he undertook much of his training. He received his medical degree withhigh honors from the Alma Mater Studiorum of Bologna and completed a medical internship. He has participated inobservership programs in Medical Retina and Uveitis at Moorfields Eye Hospital (London), Bascom Palmer EyeInstitute (Miami) and Cole Eye Institute (Cleveland). He is currently receiving his ophthalmology residency education at the University of Milan.
Jun-Rong Du is a Professor at Department of Pharmacology, West China School of Pharmacy, Sichuan University, china. She completed Doctor of Philosophy, Biology from The Hong Kong Polytechnic University 2002-2006.Prof. Du's group has done a lot of valuable work in the field of Cardio-Cerebral vascular Pharmacology, especially in novel neuroprotectants from Medical plants. Over the last decade, she was in charge of more than 10 projects, including grants from National Natural Science Foundation and Sichuan province. Prof. Du maintains an active research group. She has successfully supervised 10 Ph.D students and 38 graduate students,
Jun-Rong Du is a Professor at Department of Pharmacology, West China School of Pharmacy, Sichuan University, china. She completed Doctor of Philosophy, Biology from The Hong Kong Polytechnic University 2002-2006.Prof. Du's group has done a lot of valuable work in the field of Cardio-Cerebral vascular Pharmacology, especially in novel neuroprotectants from Medical plants. Over the last decade, she was in charge of more than 10 projects, including grants from National Natural Science Foundation and Sichuan province. Prof. Du maintains an active research group. She has successfully supervised 10 Ph.D students and 38 graduate students, and has contributed to chapters of 3 monographs and books. The published academic journal papers are more than 100 pieces, with over 40 of them in SCI journals. Five new drugs have been development with her major or lesser contribution. Nine Chinese patents have been applied, of which 4 were granted. Research interest includes Pathogenesis of Neurodegerative Diseases, Cardio-Cerebral Vascular Pharmacology.
Chi-Feng Hung is a Associate Dean of the College of Medicine and Director of Big Data Center at Fu Jen University, received my Bachelor of Science in Pharmacy from Kaohsiung Medical University and my PhD in Pharmacology from National Taiwan University in Taiwan. I have been a full time faculty teaching Pharmacology at the School of Medicine of the university since 2002. Besides being a professor, I also took the role of being the Dean of the Office of Research and Management at Fu Jen Catholic University from 2009 to 2012, which not only gave me the opportunity to further
Chi-Feng Hung is a Associate Dean of the College of Medicine and Director of Big Data Center at Fu Jen University, received my Bachelor of Science in Pharmacy from Kaohsiung Medical University and my PhD in Pharmacology from National Taiwan University in Taiwan. I have been a full time faculty teaching Pharmacology at the School of Medicine of the university since 2002. Besides being a professor, I also took the role of being the Dean of the Office of Research and Management at Fu Jen Catholic University from 2009 to 2012, which not only gave me the opportunity to further sharpen my leadership skill and organizing ability, but also enriched my research idea in different fields. With the acknowledgeable achievement during my career, I received the exceptional outstanding young professional award from the Ministry of Education of Taiwan in 2013, and I also got the exceptionally talented researcher award from Taiwan's National Science Council in 2011~2014. My greatest research interests focus mainly on the pharmacodynamics of medications or substances, especially natural ingredients, on prevention and treatment of skin aging, retinopathy and cardiovascular diseases. With the advent of the aging society, I hope to be able to contribute my share of effort for healthy aging.
Yalin Wu was born in 1979 in Yanji, Jilin, China. He received his B.S. degree in biochemical engineering from Nanjing University of Technology in 2002, and completed his Ph.D. from Zhejiang University in chemical biology. When he graduated in the spring of 2007, he first began postdoctoral work in the lab of Prof. Koji Nakanishi at the Chemistry Department of Columbia University, and later moved to Janet R. Sparrow's lab as a postdoctoral research scientist at the Ophthalmology Department of Columbia University Medical Center. He returned to Zhejiang University in 2011 when he became a full professor at the College
Yalin Wu was born in 1979 in Yanji, Jilin, China. He received his B.S. degree in biochemical engineering from Nanjing University of Technology in 2002, and completed his Ph.D. from Zhejiang University in chemical biology. When he graduated in the spring of 2007, he first began postdoctoral work in the lab of Prof. Koji Nakanishi at the Chemistry Department of Columbia University, and later moved to Janet R. Sparrow's lab as a postdoctoral research scientist at the Ophthalmology Department of Columbia University Medical Center. He returned to Zhejiang University in 2011 when he became a full professor at the College of Pharmaceutical Sciences. In 2012, he also was an adjunct professor at the Eye Center of the Second Affiliated Hospital, School of Medicine, Zhejiang University. His research is focused on pathological mechanisms and therapies of age-related macular degeneration and recessive Stargardt disease, signal transduction of the visual cycle and drug discovery.
Dr. Minghao Jin is an Associate Professor in the Department of Ophthalmology and the Neuroscience Center of Excellence at the Louisiana State University Health Sciences Center (LSUHSC) School of Medicine, USA. Prior to assuming an assistant professor position at LSUHSC in 2008, he served as an associate research ophthalmologist at the Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, where he identified RPE65, whose mutations have been linked to retinal degenerative diseases, as the retinoid isomerase necessary for regenerating the chromophore of the visual pigments. His current research interests include 1) molecular regulatory mechanisms of the visual
Dr. Minghao Jin is an Associate Professor in the Department of Ophthalmology and the Neuroscience Center of Excellence at the Louisiana State University Health Sciences Center (LSUHSC) School of Medicine, USA. Prior to assuming an assistant professor position at LSUHSC in 2008, he served as an associate research ophthalmologist at the Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, where he identified RPE65, whose mutations have been linked to retinal degenerative diseases, as the retinoid isomerase necessary for regenerating the chromophore of the visual pigments. His current research interests include 1) molecular regulatory mechanisms of the visual cycle in normal and diseased eyes, 2) cellular and molecular bases leading to vision impairment and cell death in inherited retinal degenerative diseases, and 3) rescue of visual function in mice models for human inherited retinal diseases through pharmacological and genetic approaches. Dr. Jin's research is currently supported by a grant from NIH.
Dr. Antonio Pineiro-Ces is an Ophthalmology Consultant at the Unidad de Retina Quirurgica y Tumores Intraoculares del Adulto, Servizo de Of talmoloxia, Complexo Hospitalario Universitario de Santiago and Associate Professor Ophthalmology at the Universidade de Santiago de Compostela. He received his MD (1990) and PhD (1998) from Universidade de Santiago de Compostela (Spain). Currently Antonio focuses his clinical work and research on intraocular tumors of adults. Thus, he works in one of the reference units for the entire Spanish territory in the diagnosis, treatment and monitoring of intraocular tumors in adults (only recognized three centers of this kind in Spain).
Dr. Antonio Pineiro-Ces is an Ophthalmology Consultant at the Unidad de Retina Quirurgica y Tumores Intraoculares del Adulto, Servizo de Of talmoloxia, Complexo Hospitalario Universitario de Santiago and Associate Professor Ophthalmology at the Universidade de Santiago de Compostela. He received his MD (1990) and PhD (1998) from Universidade de Santiago de Compostela (Spain). Currently Antonio focuses his clinical work and research on intraocular tumors of adults. Thus, he works in one of the reference units for the entire Spanish territory in the diagnosis, treatment and monitoring of intraocular tumors in adults (only recognized three centers of this kind in Spain). In addition, he works in basic and translational research of biomarkers with prognostic value in uveal melanoma. He maintains important medical and scientific relationship with pathologists, molecular biologists, oncologists and radiation physicists.
Dr. Carlos Quezada is an Ophthalmologist and Retina Specialist based in Torreon, Mexico Dr. Quezada then completed a Research fellowship in Ocular Pathology at McGill University in Montreal with focus on Retinal diseases, he later pursued additional training at the California Retina Consultants and Research Foundation in Santa Barbara, California were he completed a Research Fellowship in Retinal Diseases and Vitreoretinal Surgery. He has been awarded as the 2013 Gillingham Pan-american Fellow by the PAAO, The Leonard Ellen Ocular Pathology Fellow by the Research Institute of the McGill University Health Centre and the 2013 CONACYT fellow abroad by the National
Dr. Carlos Quezada is an Ophthalmologist and Retina Specialist based in Torreon, Mexico Dr. Quezada then completed a Research fellowship in Ocular Pathology at McGill University in Montreal with focus on Retinal diseases, he later pursued additional training at the California Retina Consultants and Research Foundation in Santa Barbara, California were he completed a Research Fellowship in Retinal Diseases and Vitreoretinal Surgery. He has been awarded as the 2013 Gillingham Pan-american Fellow by the PAAO, The Leonard Ellen Ocular Pathology Fellow by the Research Institute of the McGill University Health Centre and the 2013 CONACYT fellow abroad by the National Council of Science and Technology.Dr Quezada is currently an Assistant Professor of Ophthalmology at the Universidad Autonoma de Coahuila, partner at Oftalmologia del Rosario, Consultant Vitreoretinal Specialist at Instituto de la Vision in Torreon and at Clinica de Ojos Garza Viejo in Monterrey, Mexico. He serves as a peer reviewer for Ophthalmology, Revista Mexicana de Oftalmologia and Photodiagnosis and Photodynamic Therapy. His research interests include basic and clinical projects on retinal aging and different retinal diseases, mainly vitreomacular interphase disorders, RRD, AMD and diabetic retinopathy.
Abdullah Ozkaya received his MD degree from Agean University Medical School, Turkey in 2002. After getting a high ranking in Nationwide Medical Exam of Turkey, he completed his ophthalmology residency at Tepecik Eye and Training Hospital and became a specialist of ophthalmology in 2007. He completed his retina and vitreoretinal surgery fellowship between 2010 and 2013, got his Associate Professor degree in 2015 and he currently working as the director of the retina clinic in Istanbul Beyoglu Eye Hospital, one of the primary research hospitals of the country in ophthalmology. His recognized expertises are the diagnosis and treatment
Abdullah Ozkaya received his MD degree from Agean University Medical School, Turkey in 2002. After getting a high ranking in Nationwide Medical Exam of Turkey, he completed his ophthalmology residency at Tepecik Eye and Training Hospital and became a specialist of ophthalmology in 2007. He completed his retina and vitreoretinal surgery fellowship between 2010 and 2013, got his Associate Professor degree in 2015 and he currently working as the director of the retina clinic in Istanbul Beyoglu Eye Hospital, one of the primary research hospitals of the country in ophthalmology. His recognized expertises are the diagnosis and treatment of macular diseases. He has over 50 publications in several journals. Abdullah Ozkaya research area is about anti-VEGF treatment for macular diseases. He loves reading and enriching my knowledge. Also, he is a reviewer for several journals.
I, Farideh Sharifipour, MD am Associate Professor of Ophthalmology at Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. I was born andraised in Iran. Ireceived my MD with high honors from Mashhad University of Medical Sciences, Mashhad, in 1991 and then completed Ophthalmology residency at Mashhad University of Medical Sciences in 1995.I completed glaucoma fellowship in 2009 at Shahid Beheshti University of Medical Sciences, Tehran, Iran. Recently,I have started a glaucomaresearch fellowship at Jules Stein Eye Institute, David Geffen School of Medicine at UCLA under the mentorship of Dr. Caprioli. My fields of interest include glaucoma and oxygen metabolism and
I, Farideh Sharifipour, MD am Associate Professor of Ophthalmology at Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. I was born andraised in Iran. Ireceived my MD with high honors from Mashhad University of Medical Sciences, Mashhad, in 1991 and then completed Ophthalmology residency at Mashhad University of Medical Sciences in 1995.I completed glaucoma fellowship in 2009 at Shahid Beheshti University of Medical Sciences, Tehran, Iran. Recently,I have started a glaucomaresearch fellowship at Jules Stein Eye Institute, David Geffen School of Medicine at UCLA under the mentorship of Dr. Caprioli. My fields of interest include glaucoma and oxygen metabolism and its clinical applications.
Dr. Giulio Barteselli earned his MD degree from the University of Milan-Bicocca, Italy, in 2005 and he completed his ophthalmology residency at the University of Milan, Italy, in 2011. Dr. Barteselli completed a 2-year post-doctoral research and clinical fellowship in Diseases and Surgery of the Vitreous, Retina, Uveitis and Intraocular Inflammation at the University of California San Diego. He served as an Associate Director of clinical trials and imaging department of the Jacobs Retina Center at Shiley Eye Center at the University of California San Diego. He also completed a 1-year post-doctoral research and clinical fellowship in Neuro-Ophthalmology at the
Dr. Giulio Barteselli earned his MD degree from the University of Milan-Bicocca, Italy, in 2005 and he completed his ophthalmology residency at the University of Milan, Italy, in 2011. Dr. Barteselli completed a 2-year post-doctoral research and clinical fellowship in Diseases and Surgery of the Vitreous, Retina, Uveitis and Intraocular Inflammation at the University of California San Diego. He served as an Associate Director of clinical trials and imaging department of the Jacobs Retina Center at Shiley Eye Center at the University of California San Diego. He also completed a 1-year post-doctoral research and clinical fellowship in Neuro-Ophthalmology at the University of California San Diego. Dr. Barteselli is currently an Assistant Medical Director in the Ophthalmology Department at Genentech Inc, South San Francisco CA, where he collaborates in the clinical leadership of phase II and III randomized controlled trials. His main topics are medical and surgical retina. His research focuses on new treatments strategies for age-related macular degeneration, retinal vascular diseases, and other sightseeing retinal diseases, as well as on novel high-resolution technologies for retinal imaging.
My research focuses on studying the diabetic related vascular complications, including diabetic retinopathy, diabetic vascular disease, insulin resistance and diabetic nephropathy. In addition to addressing mechanisms, our cellular and biochemical studies are meant to develop cures for diseases that affect the retina, peripheral vessel and kidney. 1).Diabetic retinopathy: Focusing on endoplasmic reticulum (ER) stress activation and interactions among ER stress, oxidative stress and inflammation in retina.2).Peripheral vascular disease (PVD): Endothelial cells in the vascular system are especially vulnerable to hyperglycemic conditions. Exploring endothelial dysfunction in diabetic setting, would aid in the search for novel approaches in the prevention of diabetes
My research focuses on studying the diabetic related vascular complications, including diabetic retinopathy, diabetic vascular disease, insulin resistance and diabetic nephropathy. In addition to addressing mechanisms, our cellular and biochemical studies are meant to develop cures for diseases that affect the retina, peripheral vessel and kidney. 1).Diabetic retinopathy: Focusing on endoplasmic reticulum (ER) stress activation and interactions among ER stress, oxidative stress and inflammation in retina.2).Peripheral vascular disease (PVD): Endothelial cells in the vascular system are especially vulnerable to hyperglycemic conditions. Exploring endothelial dysfunction in diabetic setting, would aid in the search for novel approaches in the prevention of diabetes vascular disease.3). Diabetic nephropathy: Glomerular endothelial cells and podocytes are primary sites of injury resulting in chronic kidney disease in diabetes. We investigate the function of endogenous angiogenic inhibitors in regulation of renal cells in diabetic kidney. 4). Adipocyte and insulin resistance: Studying the function of PEDF in adipogenesis, provide pivotal information for understanding the mechanisms underlying the association of PEDF,obesity and insulin resistance
Dr. John Nguyen is an Attending Ophthalmic Plastic and Reconstructive Surgeon at the West Virginia University Hospital and Consultant Staff at the Louis A. Johnson Veterans Administration Hospital. His clinical interests include management of orbital trauma and thyroid eye disease.
Xiuqian Mu, MD, PhD, is currently an assistant professor of ophthalmology and biochemistry at the State University of New York at Buffalo (SUNY-Buffalo). Dr. Mu obtained his MD from Qingdao Medical College (now Qingdao University School of Medicine), and PhD in biochemistry and molecular biology from Peking Union Medical College. He subsequently received training in molecular biology and developmental biology at the National Institutes of Health and The University of Texas MD Anderson Cancer Center. He started his own lab at SUNY-Buffalo in 2008. Dr. Mu's major research interests are the molecular and genetic mechanisms underlying the generation of the
Xiuqian Mu, MD, PhD, is currently an assistant professor of ophthalmology and biochemistry at the State University of New York at Buffalo (SUNY-Buffalo). Dr. Mu obtained his MD from Qingdao Medical College (now Qingdao University School of Medicine), and PhD in biochemistry and molecular biology from Peking Union Medical College. He subsequently received training in molecular biology and developmental biology at the National Institutes of Health and The University of Texas MD Anderson Cancer Center. He started his own lab at SUNY-Buffalo in 2008. Dr. Mu's major research interests are the molecular and genetic mechanisms underlying the generation of the diverse cell types in the central nervous system during development, using the mouse retina as his research model. He has made major contributions to our understanding of the gene regulatory network controlling the formation of the retinal ganglion cells. His current research focuses are on both retinal cell fate determination and in vitro differentiation of retinal neurons for therapeutic purposes.
Dr. Swaminathan received his PhD in Pharmaceutics from The Institute of Chemical Technology, Mumbai, India in 2011. He went on to gain postdoctoral research experience in ophthalmology mainly dealing with drug development in retinal diseases such as atrophic AMD. He further fortified his repertoire by expanding into personalized medicine using systems genetics in glaucoma and nanoparticles in autosomal dominant retinitis pigmentosa. He is currently an Assistant Professor of Ophthalmology at the University of Tennessee Health Science Center, Memphis, USA. He has published 10 research papers and 2 opinions/editorials with several others in various stages of publication. He is a guest
Dr. Swaminathan received his PhD in Pharmaceutics from The Institute of Chemical Technology, Mumbai, India in 2011. He went on to gain postdoctoral research experience in ophthalmology mainly dealing with drug development in retinal diseases such as atrophic AMD. He further fortified his repertoire by expanding into personalized medicine using systems genetics in glaucoma and nanoparticles in autosomal dominant retinitis pigmentosa. He is currently an Assistant Professor of Ophthalmology at the University of Tennessee Health Science Center, Memphis, USA. He has published 10 research papers and 2 opinions/editorials with several others in various stages of publication. He is a guest blogger for AAPS blog and medical nanotech blog. He has been a peer reviewer for over 20 journals and is associated with editorial boards of several journals. His research is highly interdisciplinary and revolves around drug formulation, pharmacokinetics, systems genetics and retinal function.
Dr. Jian-Feng He got his MD degree from , Guangzhou, 2005. He has contributed over 50 peer review publication in ophthalmic literature. Recently, his team focuses on neuroprotective drug research. His research interests include clinical research in optic neuropathy and thyroid eye disease.
Dr. Jian-Feng He got his MD degree from , Guangzhou, 2005. He has contributed over 50 peer review publication in ophthalmic literature. Recently, his team focuses on neuroprotective drug research. His research interests include clinical research in optic neuropathy and thyroid eye disease.
Dr. Baran Gencer is an Assistant Professor in the Department of Ophthalmology at the Canakkale Onsekiz Mart University of Medicine School, Turkey since 2011. He received MD from Osmangazi University Medical School, Turkey in 2000 and completed ophthalmology training at the Trakya University, Edirne, Turkey in 2008. He completed refractive surgery fellowship in 2012 at Istanbul Beyoglu Eye Research and Education Hospital, Turkey. His special interests are about refractive surgery, glaucoma and corneal diseases.
Dr. Baran Gencer is an Assistant Professor in the Department of Ophthalmology at the Canakkale Onsekiz Mart University of Medicine School, Turkey since 2011. He received MD from Osmangazi University Medical School, Turkey in 2000 and completed ophthalmology training at the Trakya University, Edirne, Turkey in 2008. He completed refractive surgery fellowship in 2012 at Istanbul Beyoglu Eye Research and Education Hospital, Turkey. His special interests are about refractive surgery, glaucoma and corneal diseases.
Originally born and raised in Southern India, Dr. John moved to Roanoke, Virginia at the age of thirteen. After completing his undergraduate studies at Wake Forest University in North Carolina, he pursued a medical degree at Boston University, and completed ophthalmology training at the Emory Eye Center in Atlanta, Georgia. At Emory, he discovered his passion for retinal diseases, and was selected to a 2 year fellowship in adult and pediatric retinal surgery at Bascom Palmer Eye Institute in Miami, Florida under the mentorship of Dr. Bill Smiddy, Dr. Harry Flynn, Dr. Phil Rosenfeld, Dr. Nina Berrocal, and
Originally born and raised in Southern India, Dr. John moved to Roanoke, Virginia at the age of thirteen. After completing his undergraduate studies at Wake Forest University in North Carolina, he pursued a medical degree at Boston University, and completed ophthalmology training at the Emory Eye Center in Atlanta, Georgia. At Emory, he discovered his passion for retinal diseases, and was selected to a 2 year fellowship in adult and pediatric retinal surgery at Bascom Palmer Eye Institute in Miami, Florida under the mentorship of Dr. Bill Smiddy, Dr. Harry Flynn, Dr. Phil Rosenfeld, Dr. Nina Berrocal, and Dr. Thomas Albini amongst others. He then returned to his alma mater, Wake Forest, in 2013 to join the Wake Forest Baptist Eye Center headed by Dr. Craig Greven, and specializes in adult and pediatric retinal surgery, with special interest in pediatric vascular diseases such as ROP, FEVR, and Coats. Research Interests include, Retinopathy of Prematurity, Use of fluorescein angiography in evaluating and managing pediatric retinal diseases, Pediatric trauma, Macular degeneration and Retinal detachments
Dr. Leyan Xu, faculty in the Department of Pathology, the Johns Hopkins University School of Medicine, received his M.D. degree from Norman Bethune University of Medical Sciences and Ph. D. degree in Peking Union Medical College Hospital. His expertise is in neuroscience and stem cell therapy. His research achievement became the principal foundation upon clinical human trials for ALS which was approved by FDA. Based on the progress, He was invited to be Scientific Advisory Board Member on Cell-based Therapy in ALS, Johnson & Johnson, 2011. His main researches are degenerative and traumatic diseases of the nervous system and cell
Dr. Leyan Xu, faculty in the Department of Pathology, the Johns Hopkins University School of Medicine, received his M.D. degree from Norman Bethune University of Medical Sciences and Ph. D. degree in Peking Union Medical College Hospital. His expertise is in neuroscience and stem cell therapy. His research achievement became the principal foundation upon clinical human trials for ALS which was approved by FDA. Based on the progress, He was invited to be Scientific Advisory Board Member on Cell-based Therapy in ALS, Johnson & Johnson, 2011. His main researches are degenerative and traumatic diseases of the nervous system and cell therapy. He has successfully developed mild repetitive concussive closed-head injury rodent model. He has revealed and analyzed visual system damage in this model. He is currently engaging in the research of traumatic brain injury (including visual system damage) and its therapy. Dr. Xu has received an American Federation for Aging Research Travel Scholarship award and an American Society for Neural Therapy and Repair Travel Award. He serves on the editorial board of a few journals.
My research interests focus on the structure and function of the proteoglycans. Current work includes studies of proteoglycans in 1) cancer, more specifically the cancer stromal reaction; 2) wound healing, cornea and skin; 3) inflammation; and 4) stem cells. Mainly conditional gene knockouts, transgenic mice, cell co-culture techniques, immunohistochemistry, proteomics and glycomics are used to define the mechanisms involved.
My research interests focus on the structure and function of the proteoglycans. Current work includes studies of proteoglycans in 1) cancer, more specifically the cancer stromal reaction; 2) wound healing, cornea and skin; 3) inflammation; and 4) stem cells. Mainly conditional gene knockouts, transgenic mice, cell co-culture techniques, immunohistochemistry, proteomics and glycomics are used to define the mechanisms involved.
Dr. Orsolya Kantor received her MD in 1997 and PhD in 2002 from the historical Semmelweis University, Budapest, Hungary. She spent her postdoctoral training at the RWTH Aachen University and at the Albert-Ludwigs University in Freiburg, Germany. Currently she works as a senior lecturer at the Department of Anatomy, Histology and Embryology at the Semmelweis University, Budapest, Hungary. Her research focuses on understanding the neuronal roles of tissue non-specific alkaline phosphatase, retinal manifestations of neurodegenerative diseases, diabetic retinopathy and retinal neurotransmission. Her other interests include haban ceramics.
Dr. Orsolya Kantor received her MD in 1997 and PhD in 2002 from the historical Semmelweis University, Budapest, Hungary. She spent her postdoctoral training at the RWTH Aachen University and at the Albert-Ludwigs University in Freiburg, Germany. Currently she works as a senior lecturer at the Department of Anatomy, Histology and Embryology at the Semmelweis University, Budapest, Hungary. Her research focuses on understanding the neuronal roles of tissue non-specific alkaline phosphatase, retinal manifestations of neurodegenerative diseases, diabetic retinopathy and retinal neurotransmission. Her other interests include haban ceramics.
Muthu Rama Krishnan Mookiah, PhD, is a R & D Project Engineer at Ngee Ann Polytechnic, Singapore. He received his PhD from Indian Institute of Technology Kharagpur, India in 2012. He was awarded MHRD fellowship (2007-2011) from government of India to pursue his PhD. Dr. Mookiah is the author of more than 40 papers in peer reviewed international journals, reviewer for many international Journals and Editorial board member for the Journal of Healthcare Technology and Management. His major research focus is to develop computerized image analysis and pattern identification tools to facilitate synergistic and correlative analysis of disease signatures across
Muthu Rama Krishnan Mookiah, PhD, is a R & D Project Engineer at Ngee Ann Polytechnic, Singapore. He received his PhD from Indian Institute of Technology Kharagpur, India in 2012. He was awarded MHRD fellowship (2007-2011) from government of India to pursue his PhD. Dr. Mookiah is the author of more than 40 papers in peer reviewed international journals, reviewer for many international Journals and Editorial board member for the Journal of Healthcare Technology and Management. His major research focus is to develop computerized image analysis and pattern identification tools to facilitate synergistic and correlative analysis of disease signatures across multiple scales and functionalities from histopathology, ultrasound and fundus images for early computerized diagnosis, and prognosis of oral cancer, breast cancer, diabetic retinopathy, diabetic maculopathy, glaucoma and age-related macular degeneration.
Gauri Shankar Shrestha is an Assistant Professor of Optometry at B. P. Koirala Lions Center for Ophthalmic Studies, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu. He received Bachelor of Optometry Degree in 2002 from Institute of Medicine, Tribhuvan University and Master of Clinical Optometry in 2007 from School of Optometry, Bharati Vidyapeeth University, Pune, India. He also received a fellowship status from International Association for Contact Lens Educators, Australia in 2009. He has been working as a Coordinator of Optometry Program in Nepal and supervising optometry student's research projects. He has acquired more than 10 years of clinical experience. He
Gauri Shankar Shrestha is an Assistant Professor of Optometry at B. P. Koirala Lions Center for Ophthalmic Studies, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu. He received Bachelor of Optometry Degree in 2002 from Institute of Medicine, Tribhuvan University and Master of Clinical Optometry in 2007 from School of Optometry, Bharati Vidyapeeth University, Pune, India. He also received a fellowship status from International Association for Contact Lens Educators, Australia in 2009. He has been working as a Coordinator of Optometry Program in Nepal and supervising optometry student's research projects. He has acquired more than 10 years of clinical experience. He has also served as a president of Nepalese Association of Optometrists from 2007 to 2009. His areas of research interests are amblyopia treatment, pediatric eye health problems, and visual impairment in older people.
All articles are fully peer reviewed, free to access and can be downloaded from our ClinMed archive.
Clinical Medical Image Library: 93.51
International Journal of Critical Care and Emergency Medicine: 92.83
International Journal of Sports and Exercise Medicine: 91.84
International Journal of Womens Health and Wellness: 91.79
Journal of Musculoskeletal Disorders and Treatment: 91.73
Journal of Geriatric Medicine and Gerontology: 91.55
Journal of Infectious Diseases and Epidemiology: 91.55
Clinical Medical Reviews and Case Reports: 91.40
International Archives of Nursing and Health Care: 90.87
International Journal of Ophthalmology and Clinical Research: 90.80
International Archives of Urology and Complications: 90.73
Journal of Clinical Nephrology and Renal Care: 90.33
Journal of Family Medicine and Disease Prevention: 89.99
Journal of Clinical Gastroenterology and Treatment: 89.54
Journal of Dermatology Research and Therapy: 89.34
International Journal of Clinical Cardiology: 89.24
International Journal of Radiology and Imaging Technology: 88.88
Obstetrics and Gynaecology Cases - Reviews: 88.42
International Journal of Blood Research and Disorders: 88.22
International Journal of Diabetes and Clinical Research: 87.97